(British Approved Name, rINN)
Drug Nomenclature
International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish):
Pharmacopoeias. In British and China
British Pharmacopoeia 2008 (Gliquidone). A white or almost white powder. Practically insoluble in water slightly soluble in alcohol and in methyl alcohol soluble in acetone freely soluble in dimethylforma-mide.
Adverse Effects, Treatment, and Precautions
As for sulfonylureas in general.
Interactions
As for sulfonylureas in general.
Pharmacokinetics
Gliquidone is readily absorbed from the gastrointestinal tract. It is extensively bound to plasma proteins and has a half-life of about 1.5 hours. It is extensively metabolised in the liver, the metabolites having no significant hypoglycaemic effect, and is eliminated chiefly in the faeces via the bile only about 5% of a dose is excreted in the urine.
Uses and Administration
Gliquidone is a sulfonylurea antidiabetic. It has been given orally in the treatment of type 2 diabetes mellitus in a usual initial dosage of 15 mg daily given as a single dose up to 30 minutes before breakfast. Dosage may be adjusted by increments of 15 mg to a usual dose of 45 to 60 mg daily in 2 or 3 unequally divided doses, the largest dose being taken in the morning with breakfast. Single doses above 60 mg and daily doses above 180 mg are not recommended.
Preparations
British Pharmacopoeia 2008: Gliquidone Tablets.
Proprietary Preparations
Austria: Glurenorm
Belgium: Glurenorm
Czech Republic: Glurenorm
Germany: Glurenorm
Greece: Devotan
Hungary: Glurenorm
Indonesia: Glurenorm
Italy: Glurenor
Poland: Glurenorm
Portugal: Glurenor †
Russia: Glurenorm
Spain: Glurenor
Thailand: Glurenor
Turkey: Glurenorm
UK: Glurenorm